California's stem cell investment decision lifts Novo Nordisk hopes  

The Danish healthcare company Novo expects to gain a quality lift in its diabetes research as California decides to invest USD 3 bn in stem cell research.

Healthcare company Novo Nordisk expects to gain a quality lift in its stem cell research for the treatment of diabetes following the recent decision by the world's 5th largest economy, California, to invest DKK 17.3 bn (USD 3 bn) in stem cell research. Novo Nordisk is involved in a large US research network which will benefit from California's investments, and since the Danish company is the most advanced in stem cell research for the treatment of diabetes, it will be a natural partner to consider, says Mads Krogsgaard Thomsen, research director at Novo Nordisk. The news is reported by financial newspaper Børsen.


Diabetes is the 7th commonest cause of death in the US. It has been estimated that around 8% of the total US population has diabetes, and although approximately 2,200 people are diagnosed with diabetes every day, around a third of all cases are thought to remain undiagnosed.


Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs about 18,700 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.


Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×